AR-V7 Biomarker Detection in mCRPC Therapy Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for selecting therapy for metastatic castration-resistant prostate cancer (mCRPC) patients are hindered by heterogeneous responses to treatments and cross-resistance, with limited diagnostic tools to accurately identify patients who would benefit from specific therapies like Androgen Receptor (AR) targeted therapies or taxane chemotherapy, due to challenges in detecting and characterizing circulating tumor cells (CTCs) and the analytical validation of low-frequency AR-V7 mRNA.
Innovation Solution
An immunofluorescent test for detecting Androgen Receptor Variant 7 (AR-V7) in fixed single CTCs from blood samples, using immunofluorescent staining and morphological characterization to identify patients with improved responses to taxane therapy compared to AR-targeted therapies, based on nuclear localization of AR-V7, which corresponds to resistance or positive response to taxane therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If AR-V7 mRNA detection is performed in CTCs to guide therapy selection, then treatment efficacy is improved, but analytical validation robustness deteriorates due to low frequency and labile mRNA measurement challenges
Solution Approach 1:
The patent replaces mRNA detection (molecular biology method) with AR-V7 protein detection using immunofluorescence staining (immunological method). This substitution avoids the analytical challenges of mRNA measurement while maintaining the ability to identify AR-V7 expressing cells for therapy selection.
Solution Approach 2:
The patent changes the detection parameter from mRNA (low frequency, labile) to protein (stable, detectable by immunofluorescence). This parameter change transforms the measurement from a challenging molecular level detection to a more robust protein level detection that can be reliably validated.
2Measurement precision
If EpCAM selected CTCs are used for AR-V7 biomarker assessment, then detection sensitivity is improved, but sampling completeness deteriorates due to inability to assess all CTC subtypes
Solution Approach 1:
The patent uses a pan-CTC detection approach that can identify all CTC subtypes regardless of EpCAM expression status. The immunofluorescence staining method detects AR-V7 protein in all CTCs including EpCAM-negative subtypes, making the assay universal across different CTC populations.
Solution Approach 2:
Instead of selecting for EpCAM-positive CTCs first and then detecting AR-V7, the patent inverts the approach by directly detecting AR-V7 protein in all CTCs without EpCAM selection. This eliminates the sampling bias toward EpCAM-positive cells and captures the full diversity of CTC subtypes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides a robust and clinically useful diagnostic tool for selecting therapy by accurately identifying mCRPC patients with improved responses to taxane therapy over AR-targeted therapies, predicting resistance to AR therapies and associating with better outcomes, thereby optimizing treatment choices.
Implementation Method 1
An immunofluorescent test for detecting Androgen Receptor Variant 7 (AR-V7) in fixed single CTCs from blood samples, using immunofluorescent staining and morphological characterization
Data Source
AI summary
The present invention provides a method of identifying a metastatic castration resistant prostate cancer (mCRPC) patient with an improved response to taxane therapy compared to androgen receptor (AR) targeted therapy comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to generate circulating tumor cell (CTC) data, wherein the analysis comprises detecting the presence of an Androgen Receptor Variant 7 (AR-V7) in said cells, and (c) evaluating the CTC data to identify a mCRPC patient with an improved response to taxane therapy compared to ARS-directed therapy therapy.